GlassScriptPhysician profile
Scott Simon Tykodi
NPI 1114002938
$24,868.05
in general payments reported to CMS, 2019-2025
10 companies · $353 in 2025
The $353 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $4,500 · 2021: $5,391 · 2022: $125 · 2023: $12K · 2024: $2,025 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,980 · Food and Beverage: $695 · Education: $7.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,015.20 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,980.00 |
| Food and Beverage | $694.99 |
| Education | $7.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14,940.57 | 2020-2023 | Welireg |
| E.R. Squibb & Sons, L.L.C. | $5,424.98 | 2020-2024 | |
| Exelixis INC. | $3,960.00 | 2021-2023 | Cabometyx |
| Aveo Pharmaceuticals, INC. | $207.19 | 2025 | |
| Clinigen, INC. | $154.79 | 2019 | |
| Telix Pharmaceuticals | $145.54 | 2025 | |
| Eisai INC. | $27.78 | 2023 | |
| Pfizer INC. | $7.20 | 2023 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Tykodi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.